On March 19, 2024, Beijing Weidejie Biotechnology Co., Ltd. (referred to as Weidejie Biotechnology) independently developed a Class I new drug long-acting Treg activator (VDJ010) clinical trial application, which was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. The indication is ulcerative colitis (UC).

　　Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD), which is a chronic, idiopathic, intermittent, recurrent inflammatory disease of unknown etiology that affects the rectum and colon. In the early stages of the disease, the condition is insidious and the severity of symptoms varies. Acute and severe cases can be life-threatening, with varying degrees of systemic symptoms such as peripheral arthritis and nodular erythema. It is divided into initial and chronic types and is most common in young adults aged 30-40. It is listed as one of the difficult to treat diseases. The incidence rate and prevalence of UC have been increasing worldwide. China has the highest incidence rate of UC in Asia.

　　VDJ010, as a self-developed long-acting Treg activator, has potential advantages such as natural structure, high activity, low dosage, and wide range of indications, and has differentiated characteristics in the international competitive landscape. This project has laid out 4 international patents and has reached the national stage.

　　About Weidejie

　　Beijing VDJBio Co., LTD. is a national high-tech enterprise registered in Haidian District, Beijing, and a specialized and innovative small and medium-sized enterprise in Beijing. Focusing on innovative antibody drug development in the field of autoimmune diseases. With a unique antibody discovery and optimization platform, a complete platform for small, medium, and industrial production of large molecule drugs, a series of antibody/fusion protein drugs for the treatment of autoimmune diseases have been developed.